Edition:
India

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

25.70USD
19 Jul 2019
Change (% chg)

$-0.45 (-1.72%)
Prev Close
$26.15
Open
$26.10
Day's High
$26.10
Day's Low
$25.55
Volume
694,944
Avg. Vol
433,413
52-wk High
$28.67
52-wk Low
$12.80

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals Q1 Loss Per Share $0.59
Thursday, 2 May 2019 

May 1 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES $63 MILLION VERSUS REFINITIV IBES ESTIMATE OF $60.7 MILLION.SEES FY 2019 SALES $280 MILLION TO $300 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT MARCH 31, 2019, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $414.3 MILLION, COMPARED TO $473.5 MILLION AT DEC 31, 2018.FY2019 REVENUE VIEW $291.2 MILLION -- REFINITIV IBES DATA.  Full Article

Acadia Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS INC - ACADIA INTENDS TO GRANT UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $30 MILLION OF ITS COMMON STOCK..ACADIA PHARMACEUTICALS INC - INTENDS TO OFFER AND SELL $200 MILLION OF ITS COMMON STOCK.  Full Article

Acadia Pharmaceuticals Reports Third Quarter 2018 Financial Results
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 SALES $58.3 MILLION VERSUS I/B/E/S VIEW $56.3 MILLION.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.58 -- THOMSON REUTERS I/B/E/S.PLAN TO DISCUSS RESULTS OF PHASE 2 CLARITY STUDY EVALUATING PIMAVANSERIN WITH FDA, INITIATE A PHASE 3 PROGRAM IN H1 2019.SEES 2018 NUPLAZID NET SALES GUIDANCE TO BE BETWEEN $220 MILLION AND $225 MILLION.SEES YEAR END 2018 CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES ON ITS BALANCE SHEET TO BE BETWEEN $160 MILLION TO $170 MILLION.  Full Article

Acadia Pharmaceuticals, Neuren Pharmaceuticals Announce Exclusive License Agreement For North American Development, Commercialization Of Trofinetide In Rett Syndrome
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR THE NORTH AMERICAN DEVELOPMENT AND COMMERCIALIZATION OF TROFINETIDE IN RETT SYNDROME.ACADIA PHARMACEUTICALS INC - -NEUREN TO RECEIVE US $10 MILLION UPFRONT PLUS POTENTIAL MILESTONES OF UP TO US $455 MILLION AND ROYALTIES.ACADIA PHARMACEUTICALS INC - NEUREN RETAINS ALL RIGHTS TO TROFINETIDE OUTSIDE OF NORTH AMERICA.ACADIA PHARMACEUTICALS - PLANS TO INITIATE PHASE 3 STUDY OF TROFINETIDE FOR TREATMENT OF RETT SYNDROME IN SECOND HALF OF 2019.ACADIA PHARMACEUTICALS - POTENTIAL MILESTONE PAYMENTS TO NEUREN CONSIST OF $105 MILLION SUBJECT TO ACHIEVEMENT OF DEVELOPMENT MILESTONES IN RETT SYNDROME.  Full Article

Acadia Pharma Q4 Loss Per Share $0.55
Wednesday, 28 Feb 2018 

Feb 27 (Reuters) - Acadia Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.55.QTRLY TOTAL REVENUES $43.6 MILLION VERSUS $12.0 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $44.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

ACADIA Pharmaceuticals Q2 loss per share $0.55
Wednesday, 9 Aug 2017 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc :Q2 sales $30.5 million.Q2 loss per share $0.55.ACADIA Pharmaceuticals Inc - ‍expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million​.ACADIA Pharmaceuticals - ‍at June 30, 2017, co's cash, cash equivalents, investment securities totaled $417.3 million, versus $529.0 million at December 31, 2016​.  Full Article

Acadia pharmaceuticals Q2 loss per share $0.55
Wednesday, 9 Aug 2017 

Aug 8 (Reuters) - Acadia Pharmaceuticals Inc :Acadia pharmaceuticals reports second quarter 2017 financial results.Q2 sales $30.5 million.Q2 loss per share $0.55.Sees fy 2017 sales $105 million to $115 million.Q2 revenue view $20 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article